Lidocaine Hci Injection, Solution
NDC Package 51662-1230-3

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Lidocaine Hci injection is lidocaine hydrochloride is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type. This formulation utilizes a injection, solution delivery system. Marketed by Hf Acquisition Co. Llc, Dba Health First, this product is identified by NDC 51662-1230 and is authorized under FDA application ANDA083158.

Identification & Billing

NDC Package Code
51662-1230-3
Package Description
10 POUCH in 1 CASE / 1 SYRINGE in 1 POUCH (51662-1230-2) / 5 mL in 1 SYRINGE
Product Code
11-Digit Billing Format
51662123003
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Lidocaine Hci
Non-Proprietary Name
Lidocaine Hci
Substance Name
Lidocaine Hydrochloride
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
Usage Information
Lidocaine hydrochloride is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type. Lidocaine hydrochloride should not be used in patients with Stokes-Adams syndrome, Wolff-Parkinson-White syndrome or with severe degrees of sinoatrial, atrioventricular or intraventricular block in the absence of an artificial pacemaker.

Regulatory & Marketing

Labeler Name
Hf Acquisition Co. Llc, Dba Health First
Product Type
Human Prescription Drug
FDA Application #
ANDA083158
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
08-25-2018
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (51662-1230). Click a package code to view its specific billing and regulatory data.

1 SYRINGE, PLASTIC in 1 CARTON / 5 mL in 1 SYRINGE, PLASTIC

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 51662-1230-3 identifies a specific commercial package of 10 pouch in 1 case / 1 syringe in 1 pouch (51662-1230-2) / 5 ml in 1 syringe of Lidocaine Hci, a human prescription drug labeled by Hf Acquisition Co. Llc, Dba Health First. This injection, solution is formulated for intravenous use and contains lidocaine hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Hf Acquisition Co. Llc, Dba Health First on August 25, 2018. The current certification is valid through December 31, 2026.

How is this Hf Acquisition Co. Llc, Dba Health First product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51662123003. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
51662-1230-3
11-Digit CMS (5-4-2)
51662-1230-03

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.